Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T,
How this was made
The 30-second read
Why it matters
Key trading inputs are (1) cash and loss trajectory, (2) financing via warrant inducement, (3) TPST-4003 trial start timing in China, and (4) TPST-2003 interim efficacy and safety signals plus manufacturing partner selection for technology transfer.
Market read
The filing provides a near-to-mid-term catalyst map (Q4 2026 dosing, H1 2027 initial data) and interim clinical readouts, alongside a material cash balance change that keeps financing risk in focus.
What to watch
The interim TPST-2003 claims are from partner-sponsored trials; investors may discount durability/transferability until larger, potentially registrational datasets and manufacturing/scale-up milestones are demonstrated.
Background
This is Tempest Therapeutics’ SEC 8-K (Item 2.02) with Q2 2026 financial results and a business update covering TPST-4003 and TPST-2003 clinical and partnership progress.
Ticker impact
Tempest reported Q2 2026 results and said TPST-4003 first patient dosing is anticipated in Q4 2026, with initial data in H1 2027.
Moderately positive bias for TPST into the next few sessions as investors digest the cash runway update and the clearer China/clinical timeline.
The filing adds multiple decision-relevant items: cash balance change, warrant inducement proceeds, and specific clinical milestones (trial start window and interim response/safety metrics). However, it is still pre-registrational and the dosing/data are months away, limiting immediate upside.
Market effects
Adds incremental read-through for in vivo CAR-T platforms, especially CD7-targeted mRNA/LNP delivery, and for China trial execution timelines.
China-focused investigator-initiated trial plans for TPST-4003 may influence sentiment around cross-border biotech development in oncology/immunology.
Highlights ongoing capital and partnership activity in clinical-stage CAR-T, which can affect peer risk appetite for similar platform stories.
Counterpoint
The cash balance fell sharply to $0.8M, so the stock may still be dominated by financing risk despite the warrant inducement and clinical updates.
Key entities
- issuerTempest Therapeutics, Inc.
Clinical-stage biotech developing in vivo CAR-T candidates, including TPST-4003 and TPST-2003.
- product_candidateTPST-4003
CD7-targeted next-generation in vivo CAR-T candidate; first patient dosing anticipated in Q4 2026 and initial data expected in H1 2027.
- partnerHebei Senlang Biotechnology
Collaboration partner for TPST-4003 development, starting an investigator-initiated trial in China.
- partnerNovatim Immune Therapeutics
Partner sponsoring and conducting TPST-2003 trials (REDEEM-1 and POEMS-1).
- contract_partnerCincinnati Children’s AGCTC
Lead contract development and manufacturing partner selected for TPST-2003 technology transfer.
